Hypothyroidism: Causes, Symptoms, Treatment & Prevention

Hypothyroidism describes a state in which target tissues receive insufficient thyroid hormone, either because the thyroid itself fails to make adequate thyroxine (primary disease) or because trophic drive from the hypothalamic–pituitary axis fails to stimulate it (central disease). Triiodothyronine—the metabolically active hormone—drives basal metabolic rate, cardiac contractility, gut motility, neurodevelopment, lipid clearance and core temperature regulation, so deficiency lands across nearly every organ system rather than within one neat clinical bucket.

In iodine-replete countries, the dominant cause is autoimmune lymphocytic destruction of thyroid follicles, often labelled Hashimoto thyroiditis. Other primary mechanisms include surgical thyroidectomy, radioactive iodine ablation for Graves disease, external neck irradiation, severe iodine deficiency or excess, transient post-partum or subacute thyroiditis, and a growing list of drug-induced patterns from amiodarone, lithium, interferon-alfa, tyrosine kinase inhibitors and immune checkpoint inhibitors. Central hypothyroidism is comparatively rare and reflects pituitary or hypothalamic disease such as macroadenoma, Sheehan syndrome, traumatic brain injury, cranial irradiation or infiltrative disorders.

Clinicians use “overt” for biochemically confirmed hormone failure (raised TSH, low free T4 in primary disease; low free T4 with inappropriately normal/low TSH in central disease) and “subclinical” for the early window of raised TSH with still-normal free T4. Severe untreated overt disease is sometimes called myxedema; the decompensated end of that spectrum—myxedema coma—remains a high-mortality emergency that nursing teams need to recognise on first contact.

Bedside language tends to compress every abnormal TSH into the single label “hypothyroid”, but management splits sharply by phase and aetiology. Mapping the patient onto a clear stage takes ten seconds and prevents both overtreatment of a mildly elevated TSH and dangerous undertreatment of decompensated disease.

↔On a small screen, swipe or scroll sideways to see the full table.

Two pitfalls deserve flagging early. Patients on LT4 with a suppressed TSH and high-normal free T4 are overtreated, not “well controlled”—iatrogenic thyrotoxicosis raises the risk of atrial fibrillation and accelerates bone loss in osteoporosis. And a low free T4 with a non-elevated TSH should never be ignored as a lab error: think central disease, recent steroid pulse, severe non-thyroidal illness or assay interference.

Many adults arrive with non-specific complaints across several visits before clinicians stitch the picture together; the symptom set is famously easy to attribute to ageing, depression, perimenopause, anaemia or chronic stress. Nursing assessments that consciously cast a wider net—skin, hair, bowel, mood, voice, cycle and exercise tolerance—catch the diagnosis sooner than tightly scripted complaint-led intake.

Common adult presentation

• Persistent fatigue with non-restorative sleep that does not respond to the usual lifestyle nudges.
• Sustained cold intolerance (extra layers indoors, low tolerance for air-conditioning).
• Modest weight gain despite stable diet—reflects falling resting energy expenditure rather than fluid retention alone.
• Stubborn constipation, dry rough skin, brittle nails and diffuse hair shedding.
• Low mood, slowed cognition, memory complaints—do not anchor on depression until thyroid function has been checked.
• Menstrual changes (heavier or longer periods, oligomenorrhoea), reduced libido, sub-fertility and pregnancy loss.
• Proximal weakness, cramps, paraesthesia and a Tinel-positive hand suggesting median nerve compression in carpal tunnel syndrome.

Examination clues

• Bradycardia, narrow pulse pressure, mild diastolic hypertension; capture with structured vital sign monitoring at every encounter.
• Periorbital and pre-tibial non-pitting puffiness (myxoedema)—coarse, pasty skin in chronic untreated disease.
• Hoarseness with slow, deep speech; macroglossia in advanced disease.
• Diffuse goitre in autoimmune cases; firm rubbery texture without tenderness in classic Hashimoto thyroiditis.
• Delayed deep tendon reflex relaxation (the classic “hung-up” reflex), best tested at the ankle.

When the script breaks

Older adults often present with isolated cognitive slowing, falls, heart failure decompensation or a refractory cardiac picture; classic thermal and skin signs may be absent. Postpartum women may oscillate through transient thyrotoxicosis before settling into hypothyroidism months after delivery. Patients with severe non-thyroidal illness can show a falsely low TSH and free T4 on routine bloods—repeat once the acute illness settles before committing to therapy.

Aetiology shapes both the conversation and the surveillance plan. Autoimmune destruction is patient-modifiable mostly through avoidance of iodine excess and structured screening; iatrogenic causes (post-thyroidectomy, post-radioactive iodine, post-irradiation) carry high probability of permanent replacement; drug-induced disease often resolves with drug change but sometimes leaves persistent need for LT4.

Primary thyroid causes

• Autoimmune thyroiditis (Hashimoto): dominant cause in iodine-replete settings; clusters with other autoimmune disease (type 1 diabetes, vitiligo, coeliac, pernicious anaemia, autoimmune adrenal disease).
• Post-surgical: total thyroidectomy and many hemithyroidectomies need lifelong replacement.
• Post-radioactive iodine: common after definitive treatment of Graves disease; expect TSH to drift up months later.
• External neck irradiation: head-and-neck oncology survivors and Hodgkin survivors; surveillance for life.
• Iodine imbalance: deficiency in low-iodine geographies; excess from kelp supplements, povidone-iodine soaks, repeated iodinated contrast.
• Subacute (de Quervain) and post-partum thyroiditis: usually transient hypothyroid phase after a thyrotoxic phase.
• Congenital hypothyroidism: agenesis, dysgenesis or dyshormonogenesis—captured by neonatal heel-prick screening in most countries.

Drug-induced patterns

• Amiodarone (iodine-rich; dual hypo- and hyperthyroid risk).
• Lithium (blocks hormone release and worsens autoimmune thyroiditis).
• Interferon-alfa, IL-2, tyrosine kinase inhibitors (sunitinib, sorafenib, lenvatinib).
• Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab)—classically biphasic: early thyrotoxicosis then permanent hypothyroidism.
• High-dose iodinated contrast in susceptible glands; bexarotene; thalidomide derivatives.

Central causes

• Pituitary macroadenoma, craniopharyngioma, Rathke cleft cyst.
• Pituitary apoplexy and Sheehan syndrome (post-partum pituitary necrosis).
• Cranial irradiation, traumatic brain injury, lymphocytic hypophysitis (more common with checkpoint inhibitors).

Modern laboratories run a TSH-led screen with reflex free T4 when TSH is abnormal. Add antibody panels and imaging only when they change management. Resist over-ordering reverse T3, total T3 and salivary tests—they generate noise rather than signal in routine primary disease.

Core biochemistry

• Serum TSH as the lead screening test; interpret against age-specific reference ranges and pregnancy-specific bands when applicable.
• Free T4 (FT4) when TSH is abnormal or central disease is suspected.
• Free T3 only when overt thyrotoxicosis is suspected; rarely informative in primary hypothyroidism.
• Anti-TPO antibodies when aetiology will alter management (subclinical decision, pregnancy planning, atypical features).
• Sodium via a sodium check and a comprehensive metabolic panel in severe disease (hyponatraemia is common).
• Cortisol via a morning cortisol assay when central disease, polyautoimmunity or any haemodynamic instability is on the table.
• Lipid panel on the same blood draw using a cholesterol profile; LDL routinely rises in untreated disease and falls with replacement.
• Full blood count via a complete blood count to detect normocytic or macrocytic anaemia (and overlap with iron deficiency anaemia).

Imaging and cytology

A thyroid ultrasound is not needed for biochemical diagnosis but is indicated for palpable nodules, asymmetry, rapid neck enlargement, suspicious lymphadenopathy or compressive symptoms. Suspicious nodules feed into the fine-needle aspiration biopsy pathway according to TIRADS or BTA U-classification stratification. Pituitary MRI is reserved for suspected central disease.

Common interpretation traps

• Non-thyroidal illness (sick-euthyroid): low free T3 ± low free T4 with low/normal TSH in critically ill patients. Do not start LT4 acutely; repeat once the patient recovers.
• Recent high-dose biotin: spuriously low TSH and high free T4 on some immunoassays—stop biotin 48–72 hours before retesting.
• Dopamine, glucocorticoids, octreotide: suppress TSH without true thyrotoxicosis.
• Heterophile antibodies and macro-TSH: suspect when biochemistry mismatches the patient; ask the lab for an alternative platform.

The pragmatic chain that nursing and primary-care teams can run from a single TSH result:

1. Classify the biochemistry. Overt primary, subclinical, central or non-thyroidal illness—everything that follows changes accordingly.
2. Confirm with a repeat TSH ± free T4 in 2–3 months for borderline subclinical results to exclude a transient drift.
3. Look for triggers and aetiology. Drug history (amiodarone, lithium, immunotherapy), recent thyroid surgery or radioiodine, postpartum window, family or personal autoimmune disease, neck irradiation.
4. Decide whom to treat now. Overt disease, pregnancy or preconception, TSH >10 mIU/L, symptomatic patients with TSH 4.5–10 mIU/L (especially with anti-TPO positivity), or rising LDL with cardiovascular risk concentration.
5. Choose a starting dose. Healthy non-elderly adult: ~1.6 µg/kg/day. Older, cardiac or long-standing severe disease: 25–50 µg/day with slow upward titration.
6. Recheck TSH and free T4 at 6–8 weeks after initiation or any dose change; titrate to symptoms plus age-appropriate TSH range.
7. Refer to endocrinology for central disease, refractory biochemistry, suspected myxedema, paediatrics, pregnancy in non-specialist hands, suspicious nodules or planned conception with autoimmunity.

↔On a small screen, swipe or scroll sideways to see the full table.

Levothyroxine — first-line for almost everyone

Oral levothyroxine remains first-line therapy worldwide. Pharmacologic predictability, a long half-life (~7 days), peripheral conversion to triiodothyronine and decades of outcome data underpin that choice. Brand-to-brand bioequivalence is acceptable but not perfect—keep patients on a single product when feasible to avoid TSH drift between refills.

• Healthy adult: ~1.6 µg/kg/day full replacement once daily on an empty stomach.
• Older adult or ischaemic heart disease: start 25–50 µg/day; rise by 12.5–25 µg every 4–6 weeks against angina symptoms and ECG.
• Pregnancy: see the dedicated section below—escalate by 20–30% on confirmation of pregnancy.
• Children and adolescents: weight-based, paediatric-endocrinology-led.
• Liquid LT4 or soft-gel capsules: consider for malabsorption, post-bariatric anatomy, gastritis or persistent TSH elevation despite adherence.

Counselling pillars

• Take with water on an empty stomach—30–60 minutes before breakfast (or at bedtime ≥3 hours after the last meal if bedtime works better).
• Separate from coffee, calcium, iron, magnesium, multivitamins, antacids, sucralfate, sevelamer and bile-acid resins by ≥4 hours.
• Do not switch brand or generic at refill without clinician knowledge—follow with a TSH 6–8 weeks later if a switch is unavoidable.
• If a dose is missed, take it the same day; if a whole day is missed, double up the next day. Avoid weekly catch-up of multiple tablets except under specialist guidance.
• Report palpitations, tremor, insomnia, heat intolerance and unintentional weight loss promptly—these signal over-replacement.

Combination LT4/LT3 therapy

ATA 2014 guidance does not endorse routine addition of liothyronine. A specialist-led trial may be considered when symptoms persist after biochemical normalisation and other causes are excluded; avoid in pregnancy, atrial fibrillation and ischaemic heart disease, and monitor closely for iatrogenic thyrotoxicosis. Desiccated thyroid extract is unstandardised; most current guidelines advise against routine use.

Special populations

• Older adults: aim for an age-appropriate TSH (often upper-half of reference range); avoid suppression to reduce atrial fibrillation risk and bone loss.
• Cardiac disease: escalate slowly under cardiology liaison; uncontrolled hypothyroidism worsens diastolic dysfunction and pericardial effusions, but rapid LT4 escalation can unmask angina.
• Adrenal insufficiency overlap: give hydrocortisone before LT4.
• Coeliac disease, post-bariatric, atrophic gastritis, H. pylori: expect higher LT4 requirement; consider liquid formulation.
• Drug-induced disease: if amiodarone or lithium cannot be stopped, replace with LT4 and continue surveillance every 2–3 months.

Maternal thyroxine is critical to fetal neurodevelopment in the first 12–14 weeks before the fetal thyroid takes over. Untreated or under-treated hypothyroidism raises the risk of miscarriage, pre-eclampsia, abruption, low birth weight and impaired neurocognitive outcomes—so the threshold for action is lower than outside pregnancy.

Key practice points

• Increase LT4 by 20–30% as soon as pregnancy is confirmed—taking two extra tablets per week is a simple, durable strategy.
• Trimester-specific TSH targets (per ATA 2017): aim <2.5 mIU/L in the first trimester and within trimester-specific reference ranges thereafter; avoid sustained suppression.
• Repeat TFTs every 4 weeks until 16–20 weeks, then again around 26–32 weeks.
• Anti-TPO positive but euthyroid: watch closely; escalation to treatment depends on TSH trajectory and recurrent miscarriage history.
• Postpartum: revert to pre-pregnancy LT4 dose immediately after delivery, then check TSH at 6 weeks postpartum to detect post-partum thyroiditis.

• Lab cadence: every dose change → TFT at 6–8 weeks. Stable maintenance → annual TFT. Pregnancy → every 4 weeks until 16–20 weeks. Add ad-hoc TFTs after starting iron, calcium, PPI, sevelamer, bile-acid resin, oestrogen-containing therapy, amiodarone, lithium, checkpoint inhibitor, after major weight change or post-bariatric surgery.
• Absorption stewardship: coach the morning fasting routine before chasing dose; document timing in clinic notes. A liquid or soft-gel preparation often resolves “refractory” TSH driven by gastritis or PPI use.
• Medication safety on the ward: reconcile community LT4 with hospital-stocked equivalent during admission via structured medication reconciliation; avoid duplicate prescriptions across brand and generic.
• High-risk dosing: treat IV LT4 as a high-alert medication with double-check protocols, particularly in myxedema-coma weight-based loading.
• Drug interactions to flag: warfarin (LT4 increases warfarin effect), insulin and oral hypoglycaemics (requirements often rise as euthyroidism returns), antiepileptics (rifampin, phenytoin, carbamazepine accelerate LT4 clearance), oestrogens (raise TBG and LT4 requirement).
• Statins: hypothyroid myopathy mimics statin myopathy; check TSH before adding atorvastatin in patients with raised CK or muscle symptoms—LDL often falls back into target with replacement alone.
• Documentation: record dose, timing relative to food, brand, ferritin, vitamin D, coeliac serology and last TFT in a single line for handover via structured nursing handoff.
• Endocrinology referral: central disease, refractory biochemistry, pregnancy in non-specialist hands, paediatric or adolescent disease, suspected myxedema, suspicious nodules, drug-induced disease where the precipitating drug is essential.

Vital signs

• Heart rate via manual pulse—watch for bradycardia in untreated disease and tachycardia in over-replacement.
• Blood pressure—mild diastolic hypertension common; hypotension in myxedema coma.
• Core temperature—watch for hypothermia in severe disease.
• Respiratory rate and SpO₂—hypoventilation with hypercapnia heralds decompensation.

Targeted assessment

• Mental status with a baseline neurological assessment on admission; repeat with any clinical change.
• Weight, oedema (periorbital, tibial, sacral), bowel pattern, urine output.
• Skin for myxoedema texture, hair thinning, brittle nails.
• Voice and swallow for hoarseness or compressive goitre symptoms.
• Mood, sleep and cognition each visit—document trends rather than single snapshots.

Red flags requiring escalation

• New altered mental status, hypothermia <35.5 °C or hypoventilation in a hypothyroid patient.
• Resting tachycardia >110/min, palpitations or new atrial fibrillation on a known LT4 dose—suspect over-replacement.
• Worsening angina, breathlessness or peripheral oedema after recent dose escalation in older or cardiac patients.
• New stridor, dysphagia or rapidly enlarging neck mass.
• Suicidal ideation associated with severe hypothyroid depression—escalate via mental health pathway while normalising biochemistry.

Untreated or under-treated

• Cardiovascular: dyslipidaemia, accelerated coronary disease, diastolic dysfunction, pericardial effusion, decompensated heart failure.
• Reproductive: menorrhagia or oligomenorrhoea, anovulation, sub-fertility, recurrent miscarriage, pregnancy complications.
• Neuropsychiatric: low mood, anxiety, cognitive slowing, peripheral neuropathy, carpal tunnel syndrome, rare myxedema madness.
• Metabolic: weight gain, hyponatraemia from impaired free water clearance, normocytic or macrocytic anaemia.
• Myxedema coma: the decompensated end-stage—high-mortality medical emergency.

From over-treatment

• Iatrogenic thyrotoxicosis: palpitations, tremor, insomnia, heat intolerance, weight loss.
• Atrial fibrillation, particularly in older adults and those with structural heart disease.
• Accelerated bone loss and increased fracture risk; relevant to postmenopausal women on long-term LT4.

Most autoimmune disease is not preventable in any meaningful sense, but several clinician-modifiable strands matter. Maintain adequate—not excessive—iodine intake; counsel against megadose kelp and iodine supplements in patients with autoimmune thyroid disease. Build TFT baselines before starting amiodarone, lithium, interferon-alfa, tyrosine kinase inhibitors and immune checkpoint inhibitors, and surveil every 2–3 months on therapy. Screen high-risk groups (women planning pregnancy with personal or family autoimmune disease, post-radioactive iodine, post-thyroidectomy, post-neck irradiation, type 1 diabetes, Down syndrome, Turner syndrome). Universal population screening is not endorsed by USPSTF, but case finding remains appropriate when clinical suspicion arises.

Most adults achieve durable euthyroidism on once-daily levothyroxine with annual review. Symptom resolution often lags biochemistry by weeks to months; counsel patients early to set realistic expectations. Cardiovascular and lipid trajectories typically improve once LT4 is in target range. Pregnancy outcomes approach those of the general population when TSH is controlled before and during pregnancy. Mortality is low overall—except in myxedema coma, where it remains 25–60% even with optimal critical care—so prevention through reliable replacement and absorption stewardship is the single most useful long-term outcome lever.

Subtle deterioration

The hypothyroid patient who deteriorates rarely arrives shouting. Watch for the gradual curve: temperature drifting down half a degree per shift, respiratory rate edging into the low teens, mentation that becomes “a little vague today”, and a sodium that has slipped from 138 to 130 over a week. None of those points alone trigger a rapid response, but pattern recognition reaches for the cortisol and IV access ahead of the call.

Communication friction

Patients who feel persistently unwell despite a “normal” TSH need their experience taken seriously rather than dismissed; check absorption logistics, ferritin, vitamin B12, vitamin D, coeliac serology and depression screening, and keep the door open for specialist re-evaluation. Counter influencer-driven advice (desiccated thyroid “naturals”, iodine megadosing, T3 from unregulated sources) with calm physiology rather than confrontation.

Bedside checklist

• Confirm fasting morning dosing logistics that the patient can sustain at home—not the textbook ideal that fails by Tuesday.
• Audit supplement stacks, especially kelp, iodine, biotin, calcium and iron.
• Spot mood disorder overlap and refer; do not fold psychiatric care into endocrine review alone.
• Respect handoff: document dose, brand, last TFT, last dose change, ferritin and any interacting drug introduced this admission.

Initial bundle: ABCDE primary survey, IV access, arterial blood gas, cortisol and TFT bundle, full electrolytes, blood cultures and infection screen for the precipitant. Empirical IV hydrocortisone before thyroid hormone if adrenal insufficiency is in the differential. IV levothyroxine ± liothyronine under critical-care supervision. Passive rewarming (avoid aggressive surface warming because of vasodilation-related hypotension). Avoid sedatives that depress respiratory drive. Anticipate ICU admission and senior input from endocrinology and intensive care without delay.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient assignment, ordered response, matrix matching and cloze completion on the topic of hypothyroidism biochemistry, levothyroxine absorption traps, pregnancy escalation and myxedema coma resuscitation—matched to Clinical Judgment Measurement Model layering of cues before action.